Med Communications’ newest service area, Regulatory Writing, offers support across all stages of clinical drug development: Under the leadership of department director Ann Winter-Vann, who has more than 18 years…
Our newest department, Regulatory Writing, is led by Dr. Ann Winter-Vann. Ann received her PhD in Molecular Cancer Biology from Duke University, where she was supported by a fellowship from…
Med Communications’ Ann Winter-Vann, director of Regulatory Writing, and Jill Kembel, Business Development Lead, are at the AMWA conference in Phoenix, Arizona, this week. Ann is presenting a sold-out workshop…
Med Communications is at the World Drug Safety Congress Americas in Boston this week. Our Global Head of Pharmacovigilance and Drug Safety, Dr. Maria Anitan, will be participating in a…
Next week is National Veterans Small Business Week in America. During this annual celebration, the U.S. Small Business Administration honors veteran, service member, and military spouse small business owners nationwide….
Ann Winter-Vann, director of Regulatory Writing at Med Communications, will present a workshop on Thursday, November 6 at 2 pm during the AMWA conference in Phoenix, Arizona. This sold-out workshop,…
Med Communications’ Global Head of Pharmacovigilance and Drug Safety will be participating in a panel discussion on Global Pharmacovigilance and Regulatory during the World Drug Safety Congress Americas, to be…
A mid-size pharma company was amending its Phase 2 protocol when our regulatory writer noted a discrepancy in the study objectives. Addressing this issue early prevented the client from needing…
AMCP formulary dossiers provide a comprehensive collection of US clinical and economic evidence for new and existing medical drugs, tests, or devices. They have been widely adopted as the industry…
Med Communications’ team of residency-trained, industry-experienced PharmD specialists offer peer-to-peer support for healthcare professionals and providers. Our continual training cycle keeps team members up to date on the latest developments…
